HoldsUp

DavidPerlmutterMD · 2025-03-24 · David Perlmutter (host), Dale Bredesen

How to Make Your Brain Ageless: Prevent Cognitive Decline & Supercharge Your Mind | Dale Bredesen

43 research-tied claims examined: 1 contradicted 5 overstated 3 context 28 supported 6 unverified

1

Contradicted by research

0:47:15Dale Bredesencontradictedlow

A study found an association between high levels of Akkermansia muciniphila in the gut and amyotrophic lateral sclerosis (ALS).

"There was one study that suggested that high Akkermansia was associated with ALS." (said at 0:47:15)

Published evidence on the gut microbiome in amyotrophic lateral sclerosis (ALS) demonstrates the inverse relationship: Akkermansia muciniphila is depleted in patients with ALS and has been shown to be protective, not associated with disease promotion or elevated levels. A landmark 2019 study in Nature showed that Akkermansia muciniphila ameliorated ALS symptoms and extended survival in transgenic ALS mouse models via nicotinamide production, while human ALS cohorts exhibited reduced abundance of beneficial commensals like Akkermansia. Although elevated Akkermansia has been reported in other neurodegenerative conditions (such as Parkinson's disease and multiple sclerosis), published ALS studies identify low, not high, Akkermansia abundance.

5

Overstated

0:05:53Dale Bredesenoverstatedvery low

A published paper demonstrates over a decade of sustained cognitive and MRI improvement in patients treated with a precision medicine approach for cognitive decline.

"we just published a paper freely available online, over a decade of improvement in some of these people—then you can't really deny it." (said at 0:05:53)

A 2024 open-access case series reported sustained cognitive improvement spanning up to a decade in selected patients undergoing a personalized, multi-component precision medicine protocol (the ReCODE protocol). However, presenting an uncontrolled case series as undeniable proof of treatment efficacy overstates the scientific strength of the evidence. Uncontrolled case series cannot rule out selection bias, practice effects, natural fluctuation, or concurrent confounders, and the study authors themselves noted that controlled, long-term cohort studies are required to establish efficacy and frequency of response.

0:22:24Dale Bredesenoverstatedlow

Chronic, long-term stress alone causes the human brain to shrink.

"And as you know, just having long-term stress will shrink your brain, that alone." (said at 0:22:24)

The speaker's claim that long-term stress alone causes the human brain to shrink is overstated. Observational and neuroimaging studies show that chronic perceived stress and elevated circulating stress hormones (such as cortisol) are associated with reduced volume in specific brain regions (notably the hippocampus and prefrontal cortex) and lower total cerebral brain volume (an association observed particularly in women in large cohort studies such as the Framingham Heart Study). However, evidence in humans is primarily cross-sectional and observational rather than definitive proof of isolated causation ('that alone'), and volume reductions are regional, variable across sexes, and influenced by genetic and environmental modifiers.

0:12:17Dale Bredesenoverstatedmoderate

The human brain contains approximately 500 trillion synapses.

"You have this beautiful network of 500 trillion synapses, and you begin to lose that as you are switching from a connection mode to a protection mode." (said at 0:12:17)

Unbiased stereological studies estimating total synapse counts in the human neocortex report approximately 150 to 164 trillion synapses (0.15 x 10^15), significantly fewer than the claimed 500 trillion.

1:01:40David Perlmutter (host)overstatedlow

Starting estrogen and progesterone replacement therapy at midlife or perimenopause provides greater Alzheimer's risk reduction than initiating it postmenopausally.

"what Dr. Lisa Mosconi demonstrated was that there really at least with estrogen/progesterone replacement that the benefits of midlife, commencing therapy at midlife, perimenopausal as opposed to waiting until postmenopausal, seem to be much better in terms of Alzheimer's risk reduction." (said at 1:01:40)

Research by Dr. Lisa Mosconi and other neuroscientists explores the 'critical window' or 'timing hypothesis' of menopausal hormone therapy (MHT), showing that estrogen exposure and early initiation during the menopausal transition are linked to preserved brain gray matter volume, metabolism, and biomarker profiles in Alzheimer's-vulnerable regions. However, claiming that starting therapy during perimenopause has been 'demonstrated' to provide clinical Alzheimer's risk reduction overstates the evidence: randomized trial data in midlife are lacking, observational data for combined estrogen-progestogen therapy show variable outcomes, and hormone therapy is not clinically approved or proven for dementia prevention.

1:01:07Dale Bredesenoverstatedlow

Progesterone plays an important functional role in physiological detoxification pathways.

"And then, of course, progesterone turns out to be very important as part of your detox mechanism." (said at 1:01:07)

While progesterone and its associated receptors (such as progesterone receptor membrane component 1, or PGRMC1) interact with hepatic cytochrome P450 (CYP) monooxygenase systems, progesterone is primarily a substrate that undergoes physiological detoxification and clearance by the liver, rather than serving as an essential driver of the body's detoxification pathways. In vitro and mechanistic reviews indicate that PGRMC1 interacts with and can modulate or even inhibit certain drug-metabolizing CYP enzymes (such as CYP2C8, CYP2C9, and CYP3A4) while activating sterol-synthesizing enzymes, rather than functioning as a general detoxification mechanism.

3

Needs context

0:06:50Dale Bredesenneeds contextmoderate

In trial data from pharmaceutical anti-amyloid therapies, patients homozygous for APOE4 (APOE4/4) deteriorated more than the control group.

"The people who were APOE4/4, and this is 7 million Americans, and in the trial, of course, it represents about 10% of overall Alzheimer's disease, they actually got worse than control. Now, of course, that wasn't mentioned in the publication, but in the evaluation of the publication by an objective third party, it was pointed out, "Well, these people actually got worse, not better."" (said at 0:06:50)

In Phase 3 clinical trial data for monoclonal anti-amyloid therapies such as lecanemab (Clarity AD) and donanemab (TRAILBLAZER-ALZ 2), overall trial populations demonstrated statistically significant slowing of cognitive and functional decline compared to placebo. However, subgroup analyses by APOE ε4 carrier status revealed marked heterogeneity: in the Clarity AD trial data evaluated during regulatory reviews and subsequent analyses, APOE ε4 homozygotes assigned to lecanemab exhibited a point estimate indicating numerically faster decline on the primary Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale compared to the placebo group. While this numerical difference did not achieve statistical significance within that specific small subgroup, it demonstrated an absence of detectable clinical efficacy and a higher rate of amyloid-related imaging abnormalities (ARIA) in APOE ε4 homozygotes compared with heterozygotes and non-carriers.

0:16:32Dale Bredesenneeds contextmoderate

Beta-amyloid is a prion, along with PrPSc and alpha-synuclein.

"So what we are proposing is that these prions—and A-beta has turned out to be a prion, as well as PrPSc, as well as alpha-synuclein—these things we already know can sit in your brain for decades protecting the brain." (said at 0:16:32)

The speaker's classification of beta-amyloid (Aβ) and alpha-synuclein alongside PrPSc reflects a prominent scientific paradigm popularized by Stanley Prusiner and colleagues, but requires context. PrPSc is the classical, universally acknowledged infectious prion responsible for transmissible spongiform encephalopathies (such as Creutzfeldt-Jakob disease and scrapie). In contrast, while Aβ and alpha-synuclein exhibit prion-like molecular mechanisms—specifically seeded templating, self-propagation, and cell-to-cell spread—classifying them formally as true 'prions' remains an expanded conceptual definition rather than an established clinical consensus. In broader biomedical literature, Aβ and alpha-synuclein are typically described as 'prion-like' self-propagating proteinopathies because they lack evidence of natural inter-individual transmissibility.

0:57:58Dale Bredesenneeds contextmoderate

Parkinson's disease occurs in approximately 1.8 men for every woman, while Alzheimer's disease affects roughly twice as many women as men.

"it's about 1.8 men for each woman. We've got women getting more Alzheimer's, almost 2 to one. We've got men getting more ALS and men getting more Parkinson's." (said at 0:57:58)

Epidemiological studies confirm sex disparities in both neurodegenerative diseases, but the exact ratios are slightly more nuanced. Meta-analyses show that Parkinson's disease is significantly more common in men than women, with an overall male-to-female ratio of approximately 1.5 (increasing with age to over 1.6 to 2.0 in older cohorts). For Alzheimer's disease, approximately two-thirds of diagnosed individuals are women (roughly a 2:1 absolute number/crude prevalence in the population), though much of this disparity is driven by women living longer on average, while age-adjusted lifetime risk estimates show a more modest excess risk for women.

28

Supported by research

0:11:08Dale Bredesensupportedmoderate

Approximately 75 million Americans have a single copy of APOE4, and 7 million Americans have two copies of APOE4.

"75 million Americans have a single copy; 7 million Americans have two copies." (said at 0:11:08)

Epidemiological and population genetics studies in the United States establish that approximately 20% to 25% of the US population carries a single APOE ε4 allele (heterozygotes), and approximately 2% carries two copies (homozygotes). Applied to the total US population (roughly 335 million), 20% to 25% corresponds to approximately 67 to 84 million Americans with a single copy of APOE4, and ~2% corresponds to approximately 6.7 to 7 million Americans with two copies (APOE4/4). The guest's figures of 75 million single-copy carriers and 7 million homozygotes align closely with standard epidemiological estimates.

0:12:17David Perlmutter (host)supportedlow

Ruth Itzhaki demonstrated the colocalization of herpes simplex virus (HSV) with beta-amyloid in human brain specimens.

"In fact, I think that Ruth Itzhaki's work kind of inferred that when she demonstrated colocalization of HSV with beta-amyloid in human specimens." (said at 0:12:17)

Ruth Itzhaki and her research group demonstrated the colocalization of herpes simplex virus type 1 (HSV-1) DNA within amyloid plaques in human brain tissue specimens (Wozniak et al., 2009, J Pathol). Using in situ polymerase chain reaction combined with immunohistochemistry and thioflavin S staining, they found that 90% of amyloid plaques in Alzheimer's disease brain tissue contained HSV-1 DNA, with 72% of the viral DNA specifically associated with plaques. Because this finding is based on observational human post-mortem tissue studies, the certainty of the overall body of evidence regarding causal etiology is low.

0:16:06Dale Bredesensupportedmoderate

Beta-amyloid, phosphorylated tau, and alpha-synuclein are antimicrobial peptides.

"there's no question amyloid is part of the response. It is an antimicrobial peptide. And guess what? p-tau is also antimicrobial. Guess what? Alpha-synuclein of Parkinson's and Lewy body and MSA, that's also antimicrobial." (said at 0:16:06)

The speaker's statement accurately reflects published research demonstrating that amyloid-beta, phosphorylated tau, and alpha-synuclein exhibit antimicrobial activity and act as effector molecules of the innate immune system. In vitro and animal models have identified antimicrobial peptide (AMP) characteristics for amyloid-beta (entrapping bacteria and viruses), phosphorylated tau (neutralizing herpes simplex virus 1), and alpha-synuclein (restricting viral and bacterial replication and modulating immune responses).

0:24:10Dale Bredesensupportedhigh

Blood levels of phosphorylated tau, specifically p-tau217, strongly correlate with brain amyloid burden and ongoing neuropathology.

"And the striking relationship between phospho-tau levels in the blood—specifically p-tau217 in the blood—and the amount of amyloid in the brain and ongoing pathology in the brain." (said at 0:24:10)

Large prospective cohort and diagnostic validation studies demonstrate that blood levels of tau phosphorylated at threonine 217 (plasma p-tau217 and %p-tau217) correlate strongly with brain amyloid-beta deposition (measured by amyloid PET) and neurofibrillary tau tangles (measured by tau PET or postmortem neuropathological examination). In multiple validation cohorts, plasma p-tau217 differentiates neuropathologically confirmed Alzheimer's disease and amyloid PET positivity with very high diagnostic accuracy (AUCs ranging from 0.89 to 0.97).

0:26:12Dale Bredesensupportedmoderate

A biomarker profile of normal p-tau, normal GFAP, and elevated neurofilament light (NfL) in blood is commonly associated with frontotemporal dementia.

"for example, if you've got a normal p-tau, a normal GFAP, but a high NfL, the first concern is frontotemporal dementia. That is a common one to give you that pattern." (said at 0:26:12)

Blood-based biomarker profiling demonstrates that the combination of normal phosphorylated tau (p-tau), normal glial fibrillary acidic protein (GFAP), and elevated neurofilament light chain (NfL) is characteristic of frontotemporal dementia (FTD). In clinical differential diagnosis panels, elevated p-tau and GFAP are hallmarks of Alzheimer's disease pathology (amyloid- and tau-related astrogliosis and phosphorylation), whereas FTD typically exhibits non-elevated p-tau and GFAP alongside marked neuroaxonal injury reflected by elevated plasma NfL.

0:17:31David Perlmutter (host)supportedvery low

In rodent models of Alzheimer's disease, microglial activity is required for beta-amyloid-mediated synapse loss and neuropathology.

"And in the rodent research, the microglial activity is fundamental for the pathological effects of the beta-amyloid. You know, when these mice are genetically selected with high levels of beta-amyloid, the real pathology, the real digestion of synapses, etc., that happens really is microglia-dependent" (said at 0:17:31)

Rodent models of Alzheimer's disease demonstrate that microglial activation and phagocytosis, mediated by the classical complement cascade (C1q, C3, and CR3), are required for beta-amyloid-induced synapse elimination and dendritic spine loss. Inhibiting microglial complement receptors or depleting microglia pharmacologically rescues synaptic spine loss and neuronal death in amyloid-accumulating mouse models (such as APP/PS1 and 5xFAD) without significantly altering amyloid-beta plaque burden. Because the supporting evidence is derived entirely from animal models, the GRADE certainty is rated as very low.

0:23:26Dale Bredesensupportedmoderate

Phosphorylation of the tau protein alters its charge and conformation, causing it to dissociate from microtubules and leading to neurite collapse.

"This same molecule, when you now have insults and you're now switching to protection mode, becomes phosphorylated, which changes its charge and changes its shape. It pops off the microtubules, which now allows the neurites to collapse" (said at 0:23:26)

Biophysical and computational modeling studies demonstrate that phosphorylation of the tau protein introduces negative electrostatic charges and induces distinct conformational changes. These changes alter the microtubule-binding region, reducing tau's affinity for tubulin and promoting its dissociation from microtubules, which destabilizes the neuronal cytoskeleton and contributes to neurite retraction and collapse.

0:25:09Dale Bredesensupportedhigh

Glial fibrillary acidic protein (GFAP) is an intermediate filament protein whose levels in blood elevate during reactive astrogliosis and brain inflammation.

"And that is glial fibrillary acidic protein that is an intermediate filament protein. So what happens when your astrocytes that are supporting your neurons now balloon up and start to react because you're in inflammation mode or because you are trying to do some rebuilding, they essentially, like the Hulk, they boom, they hyperactivate. And when they do that, they are building with GFAP, so they've got to have that as a protein that now goes up. You can again pick that up in the blood." (said at 0:25:09)

Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein predominantly expressed in astrocytes. During reactive astrogliosis triggered by central nervous system injury, inflammation, or neurodegeneration, astrocytes upregulate GFAP expression, and GFAP is subsequently released into biofluids (including blood/plasma/serum), where it serves as a well-established biomarker of astrocyte activation.

0:35:10Dale Bredesensupportedhigh

Poor glucose utilization in the temporal and parietal regions on PET scan is a hallmark of Alzheimer's disease.

"And when you look at a PET scan, that's what you see, poor glucose utilization in the temporal and parietal region. That's the hallmark of Alzheimer's disease." (said at 0:35:10)

Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) measures regional cerebral glucose metabolism. A distinct pattern of reduced glucose utilization (hypometabolism) in the temporoparietal regions of the brain is an established diagnostic hallmark of typical Alzheimer's disease.

0:35:45Dale Bredesensupportedmoderate

Research by Mary Newport and Stephen Cunnane demonstrates that exogenous ketones are beneficial for individuals with mild cognitive impairment.

"So at the beginning, we just give exogenous ketones, and as people like Mary Newport and Stephen Cunnane have shown, that is helpful for people even with MCI." (said at 0:35:45)

Published clinical research by Stephen Cunnane and colleagues, as well as work by Mary Newport, supports the claim that exogenous ketogenic supplementation can benefit brain energetics and cognitive function in cognitive impairment and mild cognitive impairment (MCI). In a 6-month randomized controlled trial led by Cunnane's team (Fortier et al., 2021), a ketogenic medium-chain triglyceride (kMCT) drink significantly improved memory recall, verbal fluency, naming, and executive processing speed in individuals with MCI compared to placebo. Newport and colleagues previously reported case-based clinical and functional improvements following administration of a ketone monoester in Alzheimer's disease.

0:36:10Dale Bredesensupportedlow

Culturing primary brain cells in vitro requires insulin in the growth medium for neuronal survival.

"When, you know, when we used to grow brain cells in a dish in the lab, which we did for years and years, you had to always include insulin in their medium or they wouldn't survive. Insulin is such a crucial trophic factor for neurons." (said at 0:36:10)

Primary neuronal culture protocols (such as those using defined serum-free supplements like B-27 or N-2) universally require insulin or related trophic factors (such as IGF-1) to support long-term neuronal survival and metabolic support in vitro. Without insulin or cross-reacting insulin-family trophic factors in serum-free defined media, cultured primary neurons rapidly undergo apoptotic cell death.

0:41:55Dale Bredesensupportedmoderate

Clinical trials show that magnesium L-threonate supplementation improves cognitive outcomes.

"I happen to like uh magnesium L-threonate for many people. Um, that and that one of the reasons I like that is because it's actually had trials, um things where there are data to actually show, yes, people did better with magnesium L-threonate." (said at 0:41:55)

Randomized, double-blind, placebo-controlled clinical trials support the claim that magnesium L-threonate supplementation improves cognitive outcomes. A 2016 trial (n=44) in adults aged 50–70 with cognitive impairment found significant improvements in overall cognitive ability and executive function with a magnesium L-threonate formulation compared to placebo. Subsequent randomized trials have shown similar benefits: a 2022 trial (n=109) reported significant improvements in memory quotient scores on the Clinical Memory Test in healthy adults, and a 2025 trial (n=100) demonstrated improvements in overall cognitive performance on the NIH Total Cognition Composite, working memory, and reaction time in adults aged 18–45. The overall evidence base is moderate in certainty due to relatively small sample sizes across individual trials.

0:48:35David Perlmutter (host)supportedlow

Studies show a reduced risk of developing Alzheimer's disease over 3 years in people using semaglutide compared to other antidiabetic agents, with the largest contrast against insulin in type 2 diabetics.

"We're seeing uh initial reports of reduced risk of development of Alzheimer's over a 3-year period of time in individuals using semaglutide, Ozempic, uh in comparison to other antidiabetic agents. And the largest difference was in comparison to the use of insulin in a type 2 diabetic." (said at 0:48:35)

A large target trial emulation study using electronic health records from over 1 million patients with type 2 diabetes (Wang et al., 2024) evaluated the incidence of first-time Alzheimer's disease diagnosis over a 3-year follow-up period. The study found that semaglutide was associated with a significant 40% to 70% reduction in risk of first-time Alzheimer's disease diagnosis compared to other antidiabetic medications, with the greatest risk reduction observed when compared to insulin (hazard ratio 0.33, 95% CI: 0.21 to 0.51). Because these findings are from observational real-world data rather than randomized controlled trials, the certainty of the evidence is low.

0:51:15Dale Bredesensupportedhigh

Head-to-head clinical comparisons show that GLP-1 receptor agonists outperform Januvia (sitagliptin).

"Of course now they've gone head-to-head Januvia with GLP-1, and the GLP-1s outperform Januvia." (said at 0:51:15)

A systematic review and meta-analysis of head-to-head randomized controlled trials confirms that GLP-1 receptor agonists are significantly more effective than sitagliptin (Januvia) in lowering glycated hemoglobin (HbA1c) and reducing body weight in adults with type 2 diabetes.

0:52:00Dale Bredesensupportedhigh

A clinical trial evaluating intranasal insulin for Alzheimer's disease or cognitive decline failed to meet its primary efficacy endpoints.

"This is the same thing as, you know, several years ago there was a trial where they tried intranasal insulin. It sounded so good: 'Let's get insulin into the brain.' Well, the problem is you may be creating—and that trial failed unfortunately" (said at 0:52:00)

A major multi-site Phase 2/3 randomized controlled trial (the SNIFF trial, NCT01767909) evaluating intranasal insulin (40 IU daily) versus placebo over 12 months in 289 adults with mild cognitive impairment or Alzheimer disease dementia failed to meet its primary efficacy endpoint. In the primary intention-to-treat analysis (n = 240), there was no statistically significant difference between intranasal insulin and placebo on the primary outcome, the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-12; difference 0.0258 points; 95% CI, -1.771 to 1.822; P = .98), nor were there differences in secondary clinical or cerebrospinal fluid outcomes.

0:52:55Dale Bredesensupportedmoderate

Amyloid-beta disrupts insulin signaling by interfering with the insulin receptor and its substrate IRS-1.

"If you look at the insulin receptor and then its interaction with IRS-1, its major signaling molecule, guess what interferes with that insulin signaling? Amyloid." (said at 0:52:55)

Preclinical models and human brain tissue studies demonstrate that amyloid-beta (Aβ) oligomers disrupt neuronal insulin signaling by triggering stress kinases such as JNK, which induces inhibitory serine phosphorylation of insulin receptor substrate-1 (IRS-1) and blocks normal insulin signaling downstream of the insulin receptor.

0:54:58Dale Bredesensupportedhigh

Metformin activates AMPK by inhibiting ATP production through the mitochondrial respiratory chain.

"The way it triggers your kinase is by preventing you from making the ATP that would normally inhibit that. So what you're really doing is you're saying, 'Okay, you're eating, you're trying to do everything to get more energetics, but I'm going to block that so that you'll have more AMP and you'll now activate your AMP kinase.'" (said at 0:54:58)

The speaker's description matches the widely recognized canonical mechanism of metformin. Metformin inhibits Complex I (NADH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, reducing cellular ATP synthesis and thereby increasing the cellular AMP:ATP (and ADP:ATP) ratio, which promotes the allosteric activation and phosphorylation of AMP-activated protein kinase (AMPK).

0:56:58David Perlmutter (host)supportedhigh

MPTP is converted into toxic MPP+ by monoamine oxidase B, and MPP+ is selectively transported into dopaminergic neurons of the substantia nigra via the dopamine transporter.

"MPTP... is metabolized to MPP+ and then becomes an issue. So the question is why just those cells, the dopaminergic neurons in the pars compacta of substantia nigra, why do they suffer? And, you know, I wondered about that for a while, and I learned that it is selectively transported into the neuron by the dopamine transporter, A; and B, that the conversion of MPTP to become the toxic MPP+ requires monoamine oxidase type B" (said at 0:56:58)

The speaker's statement accurately describes the established biochemical mechanism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity. In the brain (primarily in glial cells), MPTP is bioactivated and oxidized by monoamine oxidase B (MAO-B) into the toxic metabolite MPP+ (1-methyl-4-phenylpyridinium). MPP+ is then selectively taken up into dopaminergic neurons of the substantia nigra pars compacta via the plasma membrane dopamine transporter (DAT), where it accumulates and inhibits mitochondrial complex I, leading to selective dopaminergic neuronal death.

0:59:54David Perlmutter (host)supportedlow

Maneb and mancozeb are fungicides that act as mitochondrial toxins.

"Maneb and mancozeb being fungicides that are still sold online, which are mitochondrial toxins, to be used on our vegetable gardens." (said at 0:59:54)

Maneb and mancozeb are manganese- and zinc-containing ethylene-bis-dithiocarbamate (EBDC) fungicides widely demonstrated in cellular and isolated mitochondrial models to act as mitochondrial toxins. In vitro and animal studies show that exposure to both maneb and mancozeb impairs mitochondrial function by inhibiting electron transport chain complexes (including NADH-linked respiration and complex I-V activity), causing mitochondrial membrane depolarization, uncoupling oxidative phosphorylation, depleting cellular ATP, and triggering reactive oxygen species generation.

0:59:33Dale Bredesensupportedmoderate

Exposure to organic toxicants such as trichloroethylene (TCE), perchloroethylene (PCE), dieldrin, and paraquat contributes to the risk and pathology of Parkinson's disease.

"I would mention, as you know, the common things that are driving this in that particular network are the organic toxicants. You mentioned MPP+, MPTP, but it's the things like trichloroethylene and perchloroethylene and dieldrin and paraquat" (said at 0:59:33)

Extensive epidemiological and mechanistic literature supports the link between exposure to organic toxicants—including industrial solvents like trichloroethylene (TCE) and perchloroethylene (PCE), as well as pesticides like paraquat and dieldrin—and an increased risk and hallmark pathology of Parkinson's disease. These agents trigger neurotoxic pathways including mitochondrial complex I inhibition, oxidative stress, neuroinflammation, and selective dopaminergic neuron degeneration in the substantia nigra.

0:58:00Dale Bredesensupportedhigh

Amyotrophic lateral sclerosis (ALS) occurs more frequently in men than in women.

"We've got men getting more ALS and men getting more Parkinson's." (said at 0:58:00)

Epidemiological evidence consistently demonstrates that amyotrophic lateral sclerosis (ALS) has a higher incidence in men than in women. A systematic review and meta-analysis of 39 population-based studies found a pooled male-to-female standardized incidence ratio of 1.35 (95% CI 1.31–1.40), confirming a higher risk in men across age groups.

0:53:30David Perlmutter (host)supportedmoderate

Nitric oxide is fundamental for insulin functionality.

"and I think, you know, we recognize nitric oxide is important for perfusion, for blood supply, but also fundamental for insulin functionality." (said at 0:53:30)

The statement that nitric oxide is important for blood supply/perfusion and fundamental for insulin functionality is supported by physiological literature. Insulin signaling stimulates endothelial nitric oxide synthase (eNOS) to produce nitric oxide (NO), promoting vasodilation and capillary recruitment. This NO-mediated vascular response accounts for an estimated 25% to 40% of insulin-stimulated glucose disposal by facilitating the delivery of insulin and glucose to target tissues such as skeletal muscle.

1:01:07Dale Bredesensupportedvery low

Estradiol binding to its receptor upregulates alpha-secretase, which cleaves APP to promote non-amyloidogenic processing.

"estradiol binds to its receptor, enters the nucleus, of course affects hundreds of genes. One of the things that it turns up is the alpha-secretase that cleaves the APP to give you the connection, to give you that supportive side." (said at 1:01:07)

Preclinical in vitro and rodent studies support the mechanism described by the speaker. 17β-estradiol acting through estrogen receptors promotes the non-amyloidogenic pathway of amyloid precursor protein (APP) processing by upregulating α-secretase activity (specifically ADAM10), increasing neuroprotective soluble APPα (sAPPα) and decreasing amyloid-beta (Aβ42) accumulation. Because the evidence is derived primarily from animal and cellular models, the GRADE certainty is very low.

1:02:11David Perlmutter (host)supportedvery low

Complement C3 marks synapses for microglial phagocytosis/digestion, and synaptic binding of C3 is reduced by estradiol.

"estradiol helps reduce the binding to synapses of C3. Complement C3 labels synapses such that they are then primed for digestion from the microglial cells, and that's reduced with the presence of estradiol." (said at 1:02:11)

Preclinical and mechanistic studies support both parts of the claim. The classical complement cascade, specifically complement component C3 and its receptor CR3 on microglia, opsonizes (marks) synapses for microglial engulfment and phagocytosis during both normal development and neurodegenerative pathology. Furthermore, research demonstrates that normal levels of β-estradiol protect against this pathway: falling estradiol levels promote aberrant S-nitrosylation of C3 (SNO-C3), which enhances C3 binding and downstream microglial phagocytosis of synapses. However, because evidence for this regulatory mechanism is based on postmortem human brain tissue, animal models, and in vitro studies, the GRADE certainty is very low.

1:02:25David Perlmutter (host)supportedlow

In Alzheimer's disease brains, C3-bound synapses show a 5-fold increase in men and up to a 28-fold increase in women compared to controls.

"in Alzheimer's brains, in men, there's a five-fold increase of the C3-bound synapses, and in women, it's as much as a 28-fold increase in the Alzheimer's women of that C3 binding to the synapse to label it for digestion." (said at 1:02:25)

A 2022 postmortem and mechanistic study published in Science Advances (Yang et al., PMID 36516243) examined S-nitrosylated complement component 3 (SNO-C3) and complement-mediated synaptic elimination in human Alzheimer's disease (AD) and control brains. The authors demonstrated that complement C3 activation and synaptic binding/tagging for microglial phagocytosis are markedly elevated in AD brains in a sex-dependent manner, with female AD brains exhibiting a much larger increase (up to ~28-fold higher SNO-C3/synaptic targeting) compared to male AD brains (~5 to 6-fold increase). Because evidence is derived from postmortem human brain tissue and laboratory mechanistic models, overall certainty is low.

1:03:44David Perlmutter (host)supportedmoderate

Brain metabolic changes detectable by fluorodeoxyglucose (FDG) PET occur in people's 30s and 40s, preceding Alzheimer's cognitive symptoms by two to three decades.

"the metabolic changes that you can see on the type of scan you mentioned earlier, these fluorodeoxyglucose PET scans demonstrating brain metabolism, are happening in people's 30s and 40s, presaging the cognitive manifestations by two to three decades." (said at 1:03:44)

Published neuroimaging research supports the claim that fluorodeoxyglucose positron emission tomography (FDG-PET) can detect cerebral metabolic changes decades before the onset of Alzheimer's dementia symptoms. In a landmark comparative study of young adults aged 20 to 39, cognitively normal carriers of the APOE ε4 susceptibility allele showed significantly reduced rates of cerebral glucose metabolism in the posterior cingulate, parietal, temporal, and prefrontal cortices—the same regions characteristically affected in Alzheimer's disease—roughly two to three decades before potential clinical presentation. Subsequent studies have confirmed similar presymptomatic regional hypometabolism in middle-aged and genetic-risk cohorts.

1:06:17Dale Bredesensupportedvery low

Expressing human Alzheimer's genes in Drosophila fruit flies generated an ADHD-like phenotype with hyperactivity that responded to dextroamphetamine.

"When we put human Alzheimer genes into fruit flies, guess what? They didn't get Alzheimer's, they got ADHD. And this is published. They fit all criteria. They were more in males. It was treated by the same drugs like dextroamphetamine beautifully. They had increased movement all the time." (said at 1:06:17)

A 2015 study published in the Journal of Neurology & Neurophysiology reported that an invertebrate Drosophila melanogaster Alzheimer's model exhibited features analogous to attention deficit hyperactivity disorder (ADHD), including hyperactivity, male predominance, and a reversible response to dextroamphetamine. Because the evidence is derived solely from an animal (invertebrate) model in a single preliminary report, the certainty of evidence for human clinical implications is very low.

1:06:37Dale Bredesensupportedmoderate

Published scientific research demonstrates a relationship between ADHD and an increased risk of cognitive decline.

"And there's more and more work, as you know, published about the relationship between ADHD and cognitive decline." (said at 1:06:37)

Published systematic reviews and observational cohort studies demonstrate a significant association between attention-deficit/hyperactivity disorder (ADHD) and an increased risk of subsequent cognitive decline and dementia. A meta-analysis of cohort and case-control studies found that individuals with ADHD had a significantly elevated hazard of developing all-cause dementia (pooled HR 2.52, 95% CI 1.51–4.22). While observational data show a clear link, researchers note that additional prospective studies are required to determine the exact direct causal mechanisms.

6

No source found (not proven false)

0:02:54Dale Bredesenunverifiedvery low

An interim analysis of an ongoing randomized controlled trial comparing a precision medicine protocol to standard neurological care for cognitive decline showed a statistically significant improvement in treated patients and no statistically significant change in the control group.

"we've done essentially a halfway analysis for the entire trial, and there's a statistically significant improvement in the patients who are treated. And the control group, which is getting standard of care neurological treatment for cognitive decline, um, there is no statistically significant difference." (said at 0:02:54)

No published record matching an interim analysis of an ongoing randomized controlled trial comparing this precision medicine protocol to standard neurological care was located; this does not prove the claim false. Published peer-reviewed research by this investigator includes an uncontrolled proof-of-concept pilot study of 25 patients (published in 2022) and case series reporting cognitive improvements, which noted that a larger randomized controlled trial was warranted. However, formal peer-reviewed results or interim findings from a subsequent randomized controlled trial with a standard-of-care control arm have not been published.

0:13:46Dale Bredesenunverifiedvery low

A study published around 2023 examining brains of normal individuals, Alzheimer's patients, and Parkinson's patients found that the majority of organisms in the normal brain microbiome were oral microbiota.

"And here is a really interesting study I'm sure you're aware of, came out 2 years ago. And what they showed was just taking normal brains, Alzheimer brains, and Parkinson's brains and looking at various regions of the brain and then doing sequencing and asking what are the things that are in a quote "normal" brain microbiome... the majority of the organisms that were found in the normal brain microbiome were, guess what? Oral microbiota." (said at 0:13:46)

No published record matching the claim that a study comparing postmortem brain tissue from normal individuals, Alzheimer's patients, and Parkinson's patients identified a normal brain microbiome dominated by oral microbiota was located; this does not prove the claim false.

0:30:45David Perlmutter (host)unverifiedvery low

A published study comparing stool analysis in 20 multiple sclerosis patients versus controls found distinct species-level microbiome differences.

"one of the first published studies that we did was on a series of 20 patients with MS versus control of their stool analysis, and we found some very interesting uniqueness. And this is these are data, we're just looking at the species level." (said at 0:30:45)

No published record matching a study of stool microbiome analysis in 20 multiple sclerosis patients versus controls authored by the speaker was located; this does not prove the claim false.

0:33:24Dale Bredesenunverifiedvery low

Two late-70s ApoE4 homozygous patients with early Alzheimer's symptoms who followed the ReCODE protocol showed normalized or borderline p-tau biomarker levels.

"we've had two people recently that uh both ApoE4/4, both in their late 70s, both had symptoms about 5 years ago, were starting to have Alzheimer's disease. They both went on the protocol. They both did very well. They both just checked their p-taus, and one of them's completely normal, the other one's borderline to indeterminate." (said at 0:33:24)

No published record matching the specific claim of two late-70s ApoE4/4 homozygous patients with Alzheimer's symptoms demonstrating normalized or borderline p-tau biomarker levels after following the ReCODE protocol was located; this does not prove the claim false. While publications evaluating the ReCODE protocol and multi-factorial precision medicine interventions for cognitive decline report cognitive scores (such as MoCA) and metabolic markers in patient cohorts and case series, specific clinical data documenting p-tau normalization in this described ApoE4 homozygous patient pair have not been indexed in published peer-reviewed records.

0:54:45Dale Bredesenunverifiedvery low

A published study showed an association between metformin use and increased neurodegeneration.

"There was a study a number of years ago that showed increased neurodegeneration in people who had taken metformin." (said at 0:54:45)

No published record matching the claim that metformin use is associated with increased neurodegeneration was located; this does not prove the claim false.

1:04:44David Perlmutter (host)unverifiedvery low

Differences in infant gut microbiome composition associated with the method of birth largely normalize by two to three years of age.

"these influences on an infant microbiome based upon method of birth are pretty profound and lifelong. For the most part they self-correct at two or three years" (said at 1:04:44)

No published record matching the claim that differences in infant gut microbiome composition associated with the method of birth largely normalize by two to three years of age was located; this does not prove the claim false.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.